Evidence map›Paper›PMID 40315406›Full record

ArticleJCO clinical cancer informatics2025

Performance of Two-Phase Designs for the Time-to-Event Outcome and a Case Study Assessing the Relapse Risk Associated With B-ALL Subtypes.

Wenan Chen, Ti-Cheng Chang, Karen R Rabin, Elizabeth A Raetz, Meenakshi Devidas, Stephen P Hunger, Nilsa C Ramirez, Charles G Mullighan, Mignon L Loh, Gang Wu

Abstract read
In one paragraph

Article in JCO clinical cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenan ChenDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.ORCID 0000-0003-0379-2368
Ti-Cheng ChangCenter for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-5302-9147
Karen R RabinDepartment of Pediatrics, Baylor College of Medicine, Houston, TX.ORCID 0000-0002-4081-8195
Elizabeth A RaetzDepartment of Pediatrics, Perlmutter Cancer Center, NYU Langone Hospital, New York, NY.ORCID 0000-0002-8547-1658
Meenakshi DevidasGlobal Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-1099-3478
Stephen P HungerDepartment of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-5492-3957
Nilsa C RamirezBiopathology Center and Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH.ORCID 0000-0002-9945-9449
Charles G MullighanDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-1871-1850
Mignon L LohDepartment of Pediatrics, Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Hospital, Fred Hutch Cancer Center, University of Washington, Seattle, WA.ORCID 0000-0003-4099-4700
Gang WuCenter for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
COG U24 Funding 2026-2027U24CA196173 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Mignon Lee-Cheun Loh, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$62.5M
Support for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5M
Translating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4M
NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS P30 CA015704NCI NIH HHS P30 CA021765NCI NIH HHS R35 CA197695NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766NCI NIH HHS U24 CA196173
6 · The paper itself

Abstract

purposeTo reduce costs in genomic studies of time-to-event phenotypes like survival, researchers often sequence a subset of samples from a larger cohort. This process usually involves two phases: first, collecting inexpensive variables from all samples, and second, selecting a subset for expensive measurements, for example, sequencing-based biomarkers. Common two-phase designs include nested case-control and case-cohort designs. Additional designs include sampling subjects based on follow-up time, like extreme case-control designs. Recently an optimal two-phase design using a maximum likelihood-based method was proposed, which could accommodate arbitrary sample selection in the second phase. However, direct comparisons of this optimal design with others in terms of power and computational cost is lacking.

methodsThis study performs a direct evaluation of typical two-phase designs, including Tao's optimal design, on type I error, power, effect size estimation, and computational time, using both simulated and real data sets.

resultsResults show that the optimal design had the highest power and accurate effect size estimation under the Cox regression model. Surprisingly, logistic regression achieved similar power with much lower computational cost than a more sophisticated method. The study further applied these methods to the MP2PRT study, reporting hazard ratios of cancer subtypes on relapse risk.

conclusionRecommendations for selecting two-phase designs and analysis methods are regarding power, bias of estimated effect size, and computational time.

Indexed as

Neoplasm Recurrence, LocalResearch DesignCase-Control StudiesComputer SimulationHumans

Identifiers

PMID40315406
PMCPMC12052069

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.